Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

University of Iowa

Neither a doctor nor a teaching hospital

Research payments

$4,348,424

493 payments

Through program year 2025, University of Iowa is reported as receiving $4,348,424 in research payments, across 493 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $773,949 89
2024 Research $939,750 72
2023 Research $672,565 188
2022 Research $469,086 85
2021 Research $1,068,745 30
2020 Research $394,363 19
2019 Research $29,966 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,018,933 258 payments
  2. Novartis Pharmaceuticals Corporation $997,813 28 payments
  3. Amgen Inc. $954,840 4 payments
  4. Incyte Corporation $361,553 139 payments
  5. Merck Sharp & Dohme Corporation $327,328 8 payments
  6. Bavarian Nordic A/S $156,676 5 payments
  7. BioCryst Pharmaceuticals, Inc. $152,052 6 payments
  8. Avita Medical Americas, LLC $72,394 3 payments
  9. Pfizer Inc. $65,186 5 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $35,706 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Single Arm Prospective Open Label Pilot Study Evaluating Short-Term Safety and Efficacy of Romiplostim in Children with Inherited and Acquired Disorders of Hematopoietic Failure $954,720 2 payments
  2. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $436,135 6 payments
  3. A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $352,782 5 payments
  4. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $267,808 35 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S $246,815 93 payments
  6. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $200,427 47 payments
  7. STUDY NAME#A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm# Big Ten Cancer Research Consortium BTCRC-LUN18-153 $168,439 1 payment
  8. POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial $156,676 5 payments
  9. A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Subjects with Varying Degrees of Renal Impairment $152,052 6 payments
  10. A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies $131,433 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record